PMC:6707402 / 20162-20531 JSONTXT

{"project":"MyTest","denotations":[{"id":"31489176-7257033-30448502","span":{"begin":311,"end":313},"obj":"7257033"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"†Incidences of the adverse reactions have been calculated for all the individual studies. (min%–max%) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.\n‡ Transdermal application only.\n§ One study administered DMSO through intraarticular injection [ 38].\n¶ DMSO was administered intravenously in all studies."}

{"project":"2_test","denotations":[{"id":"31489176-7257033-30448502","span":{"begin":311,"end":313},"obj":"7257033"}],"text":"†Incidences of the adverse reactions have been calculated for all the individual studies. (min%–max%) are the lowest and highest observed incidence of an adverse reaction observed in the group of studies included.\n‡ Transdermal application only.\n§ One study administered DMSO through intraarticular injection [ 38].\n¶ DMSO was administered intravenously in all studies."}